Overview
ISO 11249:2026 provides internationally recognized guidance on the design, execution, analysis, and interpretation of clinical studies for copper-bearing intrauterine contraceptive devices (IUDs). Published by the International Organization for Standardization (ISO), this standard ensures that clinical investigations into new IUDs adhere to high scientific and ethical standards, enhancing the credibility and reliability of safety and efficacy data used by manufacturers, researchers, and regulatory bodies.
The document aligns with ISO 7439 and references ISO 14155 for broader clinical investigation requirements, supporting the development, evaluation, and regulatory approval of innovative copper-bearing IUDs in global markets.
Key Topics
- Clinical Study Planning: Outlines principles of good clinical practice, emphasizing protection of participant rights, study integrity, and data credibility. Stresses the importance of a comprehensive clinical investigation plan (CIP).
- Ethics in IUD Trials: Provides guidance for informed consent processes, ethical justification for conducting IUD trials, and highlights the need for compliance with the Declaration of Helsinki and ISO 14155.
- Device Description: Details necessary information for identifying and justifying the investigational IUD, including device characteristics, intended use, operator training, and traceability measures.
- Preliminary Investigations: Recommends systematic literature reviews, preclinical testing, and review of prior clinical experience to support trial design and endpoints.
- Risk-Benefit Assessment: Supports identification and management of potential risks and anticipated benefits, aligned with ISO 14971 risk management standards.
- Clinical Objectives and Endpoints: Defines primary endpoints (e.g., pregnancy rates, expulsion, discontinuation) and recommends secondary endpoints (e.g., bleeding, pain, perforation).
- Data Analysis and Reporting: Advises on statistical methods (such as life-table analysis), collection of clinical follow-up data, and management of censored or missing data for robust study results.
- Adverse Events and Complaints: Guides systematic collection and reporting of adverse device effects, discontinuations, and serious adverse events.
Applications
ISO 11249:2026 is a key resource for companies, investigators, and regulatory agencies involved in the development, clinical evaluation, and approval of new or modified copper-bearing IUDs. Its applications include:
- Manufacturer Guidance: Assists in designing scientifically sound clinical trials to support product claims, improve efficacy, and minimize side effects.
- Clinical Study Conduct: Informs investigators and sponsors on best practices for study design, patient recruitment, informed consent, and data collection.
- Regulatory Submissions: Provides a framework for generating robust clinical evidence required for regulatory review and market authorization.
- Risk Management: Encourages proactive identification and mitigation of safety concerns associated with IUD use and study participation.
- Global Market Access: Harmonizes requirements with major international standards, facilitating smoother entry into multiple jurisdictions by aligning with regulators’ expectations.
Related Standards
- ISO 7439: Defines clinical requirements for intrauterine devices, including efficacy thresholds and product specifications.
- ISO 14155: Specifies good clinical practice for clinical investigations of medical devices in human subjects. It covers many trial design principles referenced but not detailed in ISO 11249:2026.
- ISO 14971: Details application of risk management to medical devices, supporting risk-benefit rationale required in clinical investigation plans.
By incorporating ISO 11249:2026 into product development and clinical study processes, organizations ensure scientifically rigorous, ethically conducted, and internationally recognized contraceptive device trials, ultimately supporting improved patient outcomes and streamlined regulatory approvals.